Program
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033
Its studies are mostly in Carcinoma, Hepatocellular, led by BeOne Medicines.
Drug pageAnti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Sep 17, 20263 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 33 open or running | phase 3since Sep 17, 2026 | May 20, 2024 | Mar 31, 2027phase 2 · NCT06427941 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2024First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT06427941 · 630 planned · United States, Brazil, China and more
- Sep 17, 2026Phase 3 study in Carcinoma, HepatocellularPhase 3 reachedNCT07836530 · 492 planned · Australia, New Zealand
- Oct 27, 2026Phase 2 study in Liver NeoplasmsNCT07911683 · 100 planned
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06427941
- Mar 31, 2028Primary completion: phase 2 study in Liver NeoplasmsNCT07911683
- Sep 21, 2029Primary completion: phase 3 study in Carcinoma, HepatocellularNCT07836530
TargetBeta
“A bispecific antibody directed against both the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911683Liver Neoplasms | 2 | Not yet recruiting | Mar 31, 2028 | 100 |
| NCT07836530Carcinoma, Hepatocellular · Australia, New Zealand | 3 | Recruiting | Sep 21, 2029 | 492 |
| NCT06427941Carcinoma, Hepatocellular · United States, Brazil, China and more | 2 | Recruiting | Mar 31, 2027 | 630 |
How it is read
Names in the registry
- “BGB-B2033”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.